Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04975997 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(EXCALIBER-RRMM) | active not recruiting | Phase 3 | 939 | CelgeneINDUSTRY | 31 | Apr 3, 2026 | clinicaltrials |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients(frontMIND) | active not recruiting | Phase 3 | 899 | Incyte Corporation |
| 29 |
| Apr 1, 2026 |
| clinicaltrials |
| NCT02684708 | Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents | completed | Phase 3 | 2,921 | University of GiessenOTHER | 19 | Mar 31, 2026 | clinicaltrials |
| NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)(NexCAR19) | recruiting | Phase 2 / Phase 3 | 40 | Health Institutes of TurkeyOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | recruiting | Phase 3 | 1,000 | European Myeloma Network B.V.NETWORK | 18 | Mar 25, 2026 | clinicaltrials |
| NCT07452198 | A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 3 | 358 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493109 | Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP | recruiting | Phase 3 | 200 | Ou Bai, MD/PHDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT02405676 | BNHL-2015 for Children or Adolescents in China(BNHL-2015) | active not recruiting | Phase 2 / Phase 3 | 200 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04881838 | CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL | active not recruiting | Phase 3 | 172 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06563245 | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | recruiting | Phase 2 / Phase 3 | 96 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02845882 | LBL-2016 for Children or Adolescents in China | active not recruiting | Phase 3 | 150 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04931368 | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma(OptiMATe) | active not recruiting | Phase 3 | 331 | Klinikum StuttgartOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 3 | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 0 | Mar 18, 2026 | clinicaltrials |
| NCT02947347 | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | completed | Phase 3 | 445 | Pharmacyclics LLC.INDUSTRY | 19 | Mar 17, 2026 | clinicaltrials |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma(CARTITUDE-6) | active not recruiting | Phase 3 | 759 | Stichting European Myeloma NetworkNETWORK | 16 | Mar 17, 2026 | clinicaltrials |
| NCT00006721 | S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | completed | Phase 3 | 571 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | active not recruiting | Phase 3 | 300 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 16, 2026 | clinicaltrials |
| NCT03336333 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL(SEQUOIA) | active not recruiting | Phase 3 | 590 | BeiGeneINDUSTRY | 15 | Mar 9, 2026 | clinicaltrials |
| NCT02659293 | Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | active not recruiting | Phase 3 | 180 | University of ChicagoOTHER | 2 | Mar 4, 2026 | clinicaltrials |
| NCT03729804 | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)((COBRA)) | active not recruiting | Phase 3 | 250 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04486391 | Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | terminated | Phase 3 | 3 | BeiGeneINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | completed | Phase 3 | 1,334 | TakedaINDUSTRY | 21 | Feb 27, 2026 | clinicaltrials |
| NCT02730299 | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | completed | Phase 3 | 125 | Gamida Cell ltdINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT07414758 | Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy(T-START-M1) | recruiting | Phase 3 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma(Glo-BNHL) | recruiting | Phase 2 / Phase 3 | 210 | University of BirminghamOTHER | 7 | Feb 20, 2026 | clinicaltrials |
| NCT02684292 | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) | completed | Phase 3 | 304 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 18, 2026 | clinicaltrials |
| NCT05804032 | Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 514 | University of Heidelberg Medical CenterOTHER | 2 | Feb 18, 2026 | clinicaltrials |
| NCT07029217 | A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas | recruiting | Phase 3 | 375 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413809 | Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen | recruiting | Phase 3 | 92 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04214444 | Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab(EVAPOR) | completed | Phase 3 | 26 | University Hospital, ToursOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | recruiting | Phase 3 | 20 | Aldeyra Therapeutics, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03710603 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma(Perseus) | active not recruiting | Phase 3 | 709 | Stichting European Myeloma NetworkNETWORK | 13 | Feb 10, 2026 | clinicaltrials |
| NCT04751877 | Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | active not recruiting | Phase 3 | 270 | Poitiers University HospitalOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01358747 | Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL(AHL 2011) | completed | Phase 3 | — | Centre Hospitalier Universitaire DijonOTHER | 2 | Feb 9, 2026 | clinicaltrials |
| NCT01516580 | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | completed | Phase 3 | 482 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 10 | Feb 9, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT06097364 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma(OLYMPIA-2) | active not recruiting | Phase 3 | 733 | Regeneron PharmaceuticalsINDUSTRY | 17 | Feb 6, 2026 | clinicaltrials |
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 3 | 394 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT00572169 | UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | active not recruiting | Phase 3 | 177 | University of ArkansasOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389616 | A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | recruiting | Phase 2 / Phase 3 | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03617731 | Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) | active not recruiting | Phase 3 | 662 | University of Heidelberg Medical CenterOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(BRUIN CLL-322) | active not recruiting | Phase 3 | 600 | Loxo Oncology, Inc.INDUSTRY | 23 | Jan 29, 2026 | clinicaltrials |
| NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | recruiting | Phase 3 | 292 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07355283 | IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma | not yet recruiting | Phase 3 | 198 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65(DFCI 10-106) | active not recruiting | Phase 3 | 729 | Paul Richardson, MDOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07348575 | A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma | enrolling by invitation | Phase 3 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05006482 | Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial(GEM-S) | recruiting | Phase 3 | 668 | University of RochesterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed | Phase 3 | 1,503 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Jan 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 3, 2026source: clinicaltrials